{"id":"W4388277800","doi":"10.1016/j.oraloncology.2023.106587","title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence","year":2023,"lang":"en","type":"article","venue":"Oral Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Astellas Pharma; National Institute for Health and Care Research; Genentech; Coherus Biosciences; Novartis Pharma; Rakuten Medical; Seagen; Incyte; Eisai; National Comprehensive Cancer Network; Sanofi; Exelixis; Medpace; Yuhan; Gilead Sciences; Amgen; Pfizer; Les Laboratories Pierre Fabre; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Cetuximab; Docetaxel; Oncology; Internal medicine; Head and neck squamous-cell carcinoma; Subgroup analysis; Hazard ratio; Head and neck cancer; Chemotherapy; Radiation therapy; Cancer; Immunotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004124383,0.0003129559,0.001562898,0.0005122408,0.0000702883,0.00001082436,0.0001479621,0.0001027177,0.000249177],"category_scores_gemma":[0.0003845247,0.0002245482,0.0001747688,0.001982152,0.0002016594,0.00008555366,0.000156236,0.0003034739,0.00002545625],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00028624,"about_ca_system_score_gemma":0.0005040755,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001372294,"about_ca_topic_score_gemma":0.006003184,"domain_scores_codex":[0.9974481,0.0003724673,0.0006604198,0.0006158864,0.000311236,0.0005918766],"domain_scores_gemma":[0.9981406,0.000808993,0.0002282181,0.0003617082,0.0001117869,0.0003486484],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1315872,0.005693031,0.4535149,0.004056562,0.001381479,0.00537269,0.006380002,0.0000587273,0.001305799,0.0000262003,0.03658786,0.3540356],"study_design_scores_gemma":[0.09101252,0.04675538,0.8079409,0.0003525464,0.009387576,0.0000467187,0.002710399,0.007622947,0.001336957,0.00006855072,0.03149436,0.00127116],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940284,0.003031309,0.00004568392,0.001277877,0.0003763728,0.0005187219,0.0002441499,0.00004928877,0.0004281747],"genre_scores_gemma":[0.9971404,0.001245589,0.0004150347,0.0002016648,0.00004265589,0.0001268094,0.0001563912,0.0000273598,0.0006440582],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.354426,"threshold_uncertainty_score":0.9156811,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07502603304476131,"score_gpt":0.3833777990868101,"score_spread":0.3083517660420488,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}